CN103282364B - 咪唑并[4,5-c]喹啉-2-酮化合物及其作为pi3激酶/mtor双重抑制剂的用途 - Google Patents

咪唑并[4,5-c]喹啉-2-酮化合物及其作为pi3激酶/mtor双重抑制剂的用途 Download PDF

Info

Publication number
CN103282364B
CN103282364B CN201280005256.0A CN201280005256A CN103282364B CN 103282364 B CN103282364 B CN 103282364B CN 201280005256 A CN201280005256 A CN 201280005256A CN 103282364 B CN103282364 B CN 103282364B
Authority
CN
China
Prior art keywords
cancer
imidazo
compound
mmol
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280005256.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN103282364A (zh
Inventor
D.A.巴达
M.M.梅德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN103282364A publication Critical patent/CN103282364A/zh
Application granted granted Critical
Publication of CN103282364B publication Critical patent/CN103282364B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280005256.0A 2011-01-14 2012-01-11 咪唑并[4,5-c]喹啉-2-酮化合物及其作为pi3激酶/mtor双重抑制剂的用途 Expired - Fee Related CN103282364B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161432958P 2011-01-14 2011-01-14
US61/432,958 2011-01-14
US61/432958 2011-01-14
PCT/US2012/020897 WO2012097039A1 (en) 2011-01-14 2012-01-11 Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor

Publications (2)

Publication Number Publication Date
CN103282364A CN103282364A (zh) 2013-09-04
CN103282364B true CN103282364B (zh) 2015-06-17

Family

ID=45531593

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280005256.0A Expired - Fee Related CN103282364B (zh) 2011-01-14 2012-01-11 咪唑并[4,5-c]喹啉-2-酮化合物及其作为pi3激酶/mtor双重抑制剂的用途

Country Status (39)

Country Link
US (2) US8440829B2 (OSRAM)
EP (1) EP2663564B1 (OSRAM)
JP (1) JP5891247B2 (OSRAM)
KR (1) KR101561360B1 (OSRAM)
CN (1) CN103282364B (OSRAM)
AR (1) AR084551A1 (OSRAM)
AU (1) AU2012205619B2 (OSRAM)
BR (1) BR112013017672A2 (OSRAM)
CA (1) CA2824760C (OSRAM)
CL (1) CL2013002005A1 (OSRAM)
CO (1) CO6731133A2 (OSRAM)
CR (1) CR20130289A (OSRAM)
CY (1) CY1116007T1 (OSRAM)
DK (1) DK2663564T3 (OSRAM)
DO (1) DOP2013000158A (OSRAM)
EA (1) EA022163B1 (OSRAM)
EC (1) ECSP13012764A (OSRAM)
ES (1) ES2531891T3 (OSRAM)
GT (1) GT201300180A (OSRAM)
HR (1) HRP20150135T1 (OSRAM)
HU (1) HUE024426T2 (OSRAM)
IL (1) IL227165A (OSRAM)
JO (1) JO3003B1 (OSRAM)
ME (1) ME02019B (OSRAM)
MX (1) MX2013008185A (OSRAM)
MY (1) MY164705A (OSRAM)
PE (1) PE20140864A1 (OSRAM)
PH (1) PH12013501493A1 (OSRAM)
PL (1) PL2663564T3 (OSRAM)
PT (1) PT2663564E (OSRAM)
RS (1) RS53828B1 (OSRAM)
SG (1) SG191744A1 (OSRAM)
SI (1) SI2663564T1 (OSRAM)
SV (1) SV2013004496A (OSRAM)
TN (1) TN2013000237A1 (OSRAM)
TW (1) TWI518086B (OSRAM)
UA (1) UA109921C2 (OSRAM)
WO (1) WO2012097039A1 (OSRAM)
ZA (1) ZA201304757B (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
WO2015073804A2 (en) * 2013-11-15 2015-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of blocking transmission of malarial parasite
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
TW201703769A (zh) 2015-05-08 2017-02-01 美國禮來大藥廠 用於癌症的組合療法
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
JP6359197B2 (ja) * 2015-12-15 2018-07-18 イーライ リリー アンド カンパニー がんの組合せ療法
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CA3020875A1 (en) 2016-04-12 2017-10-19 Eli Lilly And Company Combination therapy with notch and cdk4/6 inhibitors for the treatment of cancer
RU2754452C2 (ru) * 2016-04-12 2021-09-02 Эли Лилли Энд Компани Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака
ES2904880T3 (es) 2016-05-20 2022-04-06 Lilly Co Eli Terapia combinada con inhibidores de Notch y de PD-1 o PD-L1
WO2018017410A1 (en) 2016-07-22 2018-01-25 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer
WO2018063873A1 (en) * 2016-09-27 2018-04-05 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of pancreatic cancer
WO2018071307A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
MX2019009552A (es) 2017-02-17 2019-10-02 Hutchinson Fred Cancer Res Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios.
CA3080395A1 (en) 2017-11-06 2019-05-09 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
CN110386932A (zh) 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
SG11202012447YA (en) 2018-06-15 2021-01-28 Navitor Pharm Inc Rapamycin analogs and uses thereof
WO2020081329A1 (en) * 2018-10-18 2020-04-23 Camp4 Therapeutics Corporation Methods and compositions for modulating pcsk9 and angptl3 expression
US11819476B2 (en) 2019-12-05 2023-11-21 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
CN116056698B (zh) * 2020-09-21 2024-11-19 威尚（上海）生物医药有限公司 具有血脑屏障穿透能力的取代的1-(3,3-二氟哌啶-4-基)-咪唑并[4,5-c]喹啉-2-酮化合物
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
MX2024007790A (es) 2021-12-22 2024-09-06 Camp4 Therapeutics Corp Modulación de la transcripción génica utilizando oligonucleótidos antisentido dirigidos a arn reguladores.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010038165A1 (en) * 2008-09-30 2010-04-08 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
WO2010139747A1 (en) * 2009-06-04 2010-12-09 Novartis Ag 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
WO2005054237A1 (en) 2003-11-21 2005-06-16 Novartis Ag 1h-imidazoquinoline derivatives as protein kinase inhibitors
AR046845A1 (es) * 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
US8158794B2 (en) * 2005-02-23 2012-04-17 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
KR20080083270A (ko) 2005-11-04 2008-09-17 콜레이 파마시티컬 그룹, 인코포레이티드 하이드록시 및 알콕시 치환된 1에이치 이미다조퀴놀린 및방법
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
KR101445458B1 (ko) 2009-06-04 2014-10-07 노파르티스 아게 １Ｈ-이미다조［４,５-ｃ］퀴놀리논 유도체
WO2011001212A1 (en) * 2009-06-30 2011-01-06 Piramal Life Sciences Limited Imidazo [4,5-c]quinoline derivatives and their use in the treatment of tumors and/or inflammation
CN103402520A (zh) * 2010-12-06 2013-11-20 皮拉马尔企业有限公司 具有取代基的咪唑并喹啉衍生物
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010038165A1 (en) * 2008-09-30 2010-04-08 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
WO2010139747A1 (en) * 2009-06-04 2010-12-09 Novartis Ag 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES

Also Published As

Publication number Publication date
JO3003B1 (ar) 2016-09-05
NZ611541A (en) 2015-02-27
HUE024426T2 (en) 2016-01-28
JP5891247B2 (ja) 2016-03-22
US8440829B2 (en) 2013-05-14
SG191744A1 (en) 2013-08-30
SV2013004496A (es) 2017-11-07
KR101561360B1 (ko) 2015-10-16
EA201390823A1 (ru) 2013-12-30
PL2663564T3 (pl) 2015-05-29
AU2012205619A1 (en) 2013-06-27
IL227165A (en) 2016-06-30
GT201300180A (es) 2014-04-08
CO6731133A2 (es) 2013-08-15
DOP2013000158A (es) 2013-11-30
WO2012097039A1 (en) 2012-07-19
CR20130289A (es) 2013-10-07
CN103282364A (zh) 2013-09-04
JP2014502638A (ja) 2014-02-03
US8658668B2 (en) 2014-02-25
DK2663564T3 (en) 2015-01-12
EP2663564B1 (en) 2014-12-17
TWI518086B (zh) 2016-01-21
PT2663564E (pt) 2015-02-24
ECSP13012764A (es) 2013-09-30
ES2531891T3 (es) 2015-03-20
UA109921C2 (uk) 2015-10-26
HRP20150135T1 (xx) 2015-03-13
KR20130116302A (ko) 2013-10-23
HK1188454A1 (en) 2014-05-02
US20120184577A1 (en) 2012-07-19
TN2013000237A1 (en) 2014-11-10
SI2663564T1 (sl) 2015-01-30
TW201307343A (zh) 2013-02-16
MY164705A (en) 2018-01-30
ZA201304757B (en) 2014-12-23
PH12013501493A1 (en) 2021-06-02
CL2013002005A1 (es) 2013-12-27
MX2013008185A (es) 2013-08-21
ME02019B (me) 2015-05-20
US20130237562A1 (en) 2013-09-12
CA2824760C (en) 2016-03-15
EP2663564A1 (en) 2013-11-20
PE20140864A1 (es) 2014-07-19
AU2012205619B2 (en) 2015-05-21
CA2824760A1 (en) 2012-07-19
AR084551A1 (es) 2013-05-22
EA022163B1 (ru) 2015-11-30
CY1116007T1 (el) 2017-01-25
RS53828B1 (sr) 2015-06-30
BR112013017672A2 (pt) 2018-09-18

Similar Documents

Publication Publication Date Title
CN103282364B (zh) 咪唑并[4,5-c]喹啉-2-酮化合物及其作为pi3激酶/mtor双重抑制剂的用途
KR20220006139A (ko) Stat 분해제 및 이의 용도
JP6553629B2 (ja) 線維芽細胞増殖因子受容体阻害剤としてのキノロン誘導体
RU2589053C1 (ru) ПИРРОЛО[2,1-f][1,2,4]ТРИАЗИНОВОЕ СОЕДИНЕНИЕ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
ES2558780T3 (es) Imidazopiridazinas como inhibidores de la cinasa Akt
CN115297931A (zh) Smarca降解剂和其用途
CN113271940A (zh) Tyk2抑制剂和其用途
JP2006507292A (ja) 抗増殖活性（ｉｉ）を有するピリミド化合物
JP2009518340A (ja) ＥｐｈＢおよびＶＥＧＦＲ２キナーゼ阻害剤としてのピラゾロ［１，５−ａ］ピリジン−３−カルボン酸
CN116888116A (zh) Gpr84拮抗剂和其用途
JP2013530250A (ja) 二環式ピリミジン化合物
WO2020077944A1 (zh) 嘌呤系列衍生物及其制备方法和用途
WO2025049821A1 (en) Stat6 degraders and uses thereof
WO2023250430A1 (en) Bicyclic amine cdk12 inhibitors
CN104884456B (zh) PI3K和/或mTOR抑制剂
NZ611541B2 (en) Imidazo[4,5-c]quinolin-2-one compound and its use as pi3 kinase / mtor dual inhibitor
HK1188454B (en) Imidazo [4, 5 -c]quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor
CN105121442B (zh) PI3K和/或mTOR抑制剂的前药
CN105392484A (zh) 咪唑并哒嗪衍生物与有丝分裂试剂的联用药用于治疗癌症
CZ2020510A3 (cs) Substituované purinové sloučeniny jako inhibitory proteinkináz, jejich použití jako léčiva a farmaceutické přípravky obsahující tyto deriváty
HK1190142A (en) Pyridonaphthyridine pi3k/mtor dual inhibitors and preparation and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150617

Termination date: 20210111